Main Article Content
In this Cochrane Corner, we highlight the main findings of a Cochrane Review by Flumignan et al. entitled ‘Anticoagulants for people hospitalised with COVID‐19’ and discuss the implications of these findings for research and practice in South Africa. In particular, we underscore the need for additional, high‐quality, randomised controlled trials comparing different intensities of anticoagulation in patients with COVID‐19 illness. Individuals in the intensive care unit and those hospitalised with another illness who are incidentally found to be infected with SARS‐CoV‐2 should still only be treated with prophylactic‐dose low‐molecular‐weight heparin.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJCC is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
Flumignan RLG, Civile VT, Tinôcos JDDS, et al. Anticoagulants for people hospitalised with COVID‐19. Cochrane Database Syst Rev 2022;3:CD013739. https://doi.org/10.1002/14651858. CD013739.pub2
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844‐847. https://doi.org/10.1111/jth.14768Xx
Chen J, Wang X, Zhang S, et al. Characteristics of acute pulmonary embolism in patients with COVID‐19 associated pneumonia from the city of Wuhan. Clin Appl Thromb Hemost 2020;26:1‐ 8. https://doi.org/10.1177/1076029620936772
Bilalogu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalised patients with COVID‐19 in a New York City health system. JAMA 2020;324(8):799‐ 801. https://doi.org/10.1001/jama.2020.13372
Klok FA, Kruip MJ, Van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb 2020;191:145‐147. https://doi.org/10.1016/j. thromres.2020.04.013
Klok FA, Kruip MJ, Van der Meer NJ, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID‐19: An updated analysis. Thromb 2020;191:148‐150. https://doi.org/10.1016/j.thromres.2020.04.041
National Department of Health. Update on COVID‐19 (Wednesday 21 September 2022) (accessed 29 September 2022). https://sacoronavirus.co.za/2022/09/21/update‐on‐COVID‐19‐ wednesday‐21‐september‐2022/
Longchamp G, Manzocchi‐Besson S, Longchamp A, et al. Proximal deep vein thrombosis and pulmonary embolism in COVID‐19 patients: A systematic review and meta‐analysis. Thrombosis J 2021;19(1):15. https://doi.org/10.1186/s12959‐021‐00266‐x
Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. J Thromb Haemost 2020;18(7):1747. https://doi.org/10.1111/ jth.14854
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: A multicenter prospective cohort study. Intensive Care Med 2020;46(6):1089. https:// doi.org/10.1007/s00134‐020‐06062‐x
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID‐19. J Thromb Haemost 2020;18(7):1559. https://doi.org/10.1111/jth.14849
National Department of Health. Rapid reviews for therapeutics for the management of COVID‐19. Knowledge Hub (accessed 3 August 2022). https://www.health.gov.za/COVID‐19‐ rapid‐reviews/
National Institutes of Health. Antithrombotic therapy in patients with COVID‐19. COVID‐19 treatment guidelines (accessed 14 March 2023). https://www.covid19treatmentguidelines.nih.gov/ therapies/antithrombotic‐therapy/
Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID‐19: January 2022 update on the use of therapeutic‐intensity anticoagulation in acutely ill patients. Blood Adv 2022;6(17):4915‐4923. https://doi.org/10.1182/bloodadvances.2022007561